Toshiki Etani
【Educational and professional background】
March 2006 Graduated from Yamagata University School of Medicine, School of Medicine
April 2006 Initial resident, Showa Hospital, JA Aichi
Apr 2008 Urologist, Showa Hospital, JA Aichi
Jan 2011 Urologist, Toyota Kosei Hospital, JA
April 2012 Clinical Research Physician, Nagoya City University Graduate School of Medicine, Department of Nephrology and Urology
Mar 2015 Completed Doctoral program, Nagoya City University Graduate School of Medicine, Doctor of Medicine
July 2015 Urologist, Komono Kosei Hospital, JA Mie
July 2009 Assistant Professor, Department of Nephrology and Urology, Nagoya City University Graduate School of Medicine
January 2022 Lecturer (Senior Assistant Professor), Nagoya City University Graduate School of Medicine, Department of Nephrology and Urology
【Major academic societies to which he belongs 】
Japanese Urological Association (board certified physician and advisor), Japanese Society of Chemotherapy (board certified physician and councilor), Japanese Society of Palliative Medicine (board certified physician), Japanese Society of Sexually Transmitted Diseases (board certified physician), Japanese Society of Environmental Infection Control, Japanese Society of Clinical Microbiology, Japanese Cancer Association, Japanese Association for Cancer Treatment, Japanese Society of Urologic Oncology, Japanese Society of Urologic Endoscopy and Robotics (certified laparoscopic technique (Medical doctor certified in laparoscopic techniques)
Certified Cancer Therapy Physician
Infection Control Doctor
Urological robot-assisted surgery proctor (bladder, prostate, adrenal gland, kidney (ureter))
【Awards and Prizes】
June, 2014 Best Presentation Award, The 264th Annual Meeting of the Japanese Urological Association, Tokai, Japan “A case of primary immature neuroectodermal tumor of the kidney”.
June, 2016 Academic Encouragement Award (Basic Section), Japanese Society of Andrology, “NCL1, a highly selective inhibitor of lysine-specific demethylase LSD1, suppresses prostate cancer without adverse events”.
April, 2023 The Japanese Urological Association 11th Young Research Grant “Development of a novel LSD1 inhibitor and autophagy-regulated therapy for castration-resistant prostate cancer”.
December 2023 Japanese Research Group for Urinary tract infection (JRGU) Best Paper Award 2020-2022
14th August 2025
| Time | Session |
|---|---|
|
13:30
17:00
|
TICC - 1F 101B
|